Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int J Nephrol Renovasc Dis ; 13: 341-348, 2020.
Article in English | MEDLINE | ID: mdl-33239901

ABSTRACT

BACKGROUND: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis dependent CKD. METHODS: Cross-sectional study. Concentrations of creatinine, magnesium, calcium, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). RESULTS: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (>89.5pg/mL), the mean levels of FEMg and ALP were higher (p<0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02-1.23), calcium (OR = 0.45; 95% CI: 0.22-0.90), ALP (OR = 1.02; 95% CI: 1.00-1.03) and eGFR (OR = 0.92; 95% CI: 1.00-1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. CONCLUSION: In patients with non-dialysis dependent CKD, FEMg and ALP were some variables that remained associated with PTH.

2.
Prim Care Diabetes ; 7(2): 135-41, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23485345

ABSTRACT

BACKGROUND: Blacks show higher levels of HbA1c in studies with different populations and are disproportionately affected by most diabetes-related complications. AIMS: The study aims to investigate if the prevalence of altered glycated hemoglobin (HbA1c) varies with skin color and if there is a familial aggregation of either skin color and HbA1c. METHODS: The study used the CAMELIA study (Cardio-Metabolic-Renal familiar) population, conducted between June 2006 and December 2007 (cross sectional). Families were recruited from 13 Family Doctor Program Unities of Niteroi, Brazil, a highly miscegenated population. The visits included questionnaire, medical consultation, anthropometric and nutritional assessment. Blood pressure, blood/urine samples were collected. The dosage of HbA1c was performed by immunoturbidimetry in Labmax 240 equipment. RESULTS: We compare data of 241 (25.5%) Blacks, versus 422 (44.7%) Mulattos or 272 (28.8%) Whites. The groups did not differ significantly with regard to most measures. Blacks had the lowest levels of income/education, higher frequency of diabetes and hypertension (p<0.20) as higher levels of HbA1c (p<0.05) that persisted after adjusting for possible confounders. Among blacks, the correlations between siblings of HbA1c were higher than among white/mulatto, reaching 86% versus 50%, respectively. CONCLUSION: Those results indicate that Brazilian Blacks patients must have more attention, focusing on diabetes preventive care. Longitudinal studies are needed to address the question if the altered level of HbA1c has a real clinical impact.


Subject(s)
Black People , Diabetes Mellitus/blood , Diabetes Mellitus/genetics , Glycated Hemoglobin/analysis , Primary Health Care , Public Sector , Skin Pigmentation , White People , Adult , Biomarkers/blood , Black People/genetics , Brazil/epidemiology , Chi-Square Distribution , Cross-Sectional Studies , Diabetes Mellitus/diagnosis , Diabetes Mellitus/physiopathology , Female , Gene-Environment Interaction , Genetic Predisposition to Disease , Glycated Hemoglobin/genetics , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Pedigree , Prevalence , Risk Factors , Skin Pigmentation/genetics , Socioeconomic Factors , White People/genetics , Young Adult
3.
Value Health Reg Issues ; 1(2): 254-256, 2012 Dec.
Article in English | MEDLINE | ID: mdl-29702909

ABSTRACT

Biosimilars are biologics developed to compete with originator biologics that have been on the market for a long time and lost their patent and market protection. The WHO guidelines on evaluation of Biosimilars provide clear guidance for regulators on how to develop and gain approval for these products. The aim of this paper is to inform of the current status of development in regulation of Biosimilars in Brazil according WHO Guidelines. The result of the comparison shows the Brazilian regulation conflicts with the principles of the WHO guidelines.

4.
Physis (Rio J.) ; 21(2): 395-416, 2011. ilus, tab
Article in Portuguese | LILACS | ID: lil-596059

ABSTRACT

O artigo visa a estimar o custo direto médico do tratamento hospitalar de pacientes idosos com fraturas de fêmur proximal, no Hospital Municipal Lourenço Jorge, na cidade do Rio de Janeiro. Estudo observacional, prospectivo, para estimar a utilização de recursos e custos diretos médicos associados à hospitalização por fratura de fêmur proximal em idosos, em 2007 e 2008, sob a perspectiva do prestador de serviços. Foi utilizado um instrumento de coleta de dados através do qual foram registrados recursos identificados na revisão prospectiva dos prontuários. Aos recursos utilizados foram atribuídos custos em reais (R$) baseando-se em valores do ano 2010. Foram realizadas análises descritivas dos custos e utilização de recursos, bem como avaliada a associação de variáveis clínicas e demográficas com o custo final observado. Foram incluídos 82 pacientes, 81,7 por cento do sexo feminino, idade média de 76,96 anos, hospitalização média de 12,66 dias. A mediana de custo por paciente foi de R$ 3.064,76 (IC95 por cento: 2.817,63 a 3.463,98). Hospitalização clínica e procedimento cirúrgico foram responsáveis por 65,61 por cento e 24,94 por cento dos custos, respectivamente. Pacientes submetidos ao tratamento cirúrgico até o quarto dia de hospitalização apresentaram mediana de custos menor do que pacientes submetidos após o quarto dia (R$ 2.136,31 e R$ 3.281,45, p<0,00001). Observou-se também diferença significativa nos custos finais por tipo de procedimento cirúrgico realizado. O custo do tratamento das fraturas de fêmur proximal no idoso foi significativamente maior nos pacientes submetidos à cirurgia após o quarto dia de hospitalização. Hospitalização clínica e procedimento cirúrgico foram os principais componentes do custo final observado.


This paper aims to assess direct medical costs associated to hospital treatment of hip fractures in the elderly in the Municipal Hospital Lourenço Jorge (HMLJ), Rio de Janeiro. Observational, prospective study to assess resource utilization and direct medical costs associated to elderly hip fracture hospitalization in 2007 and 2008, under the health care provider perspective. A standard data collection instrument was used to register identified resources during prospective medical charts review. The resource utilization was converted into Brazilian Real (R$), based on 2010 prices. Descriptive analysis of costs and resource utilization and their association with clinical and demographic variables were performed. Eighty two patients were included, 81.7 percent female, mean age of 76.96 years, hospitalization mean time of 12.66 days. Median total costs per patient were R$ 3,064.76 (IC95 percent: 2,817.63 - 3,463.98). Clinical hospitalization and surgical procedure were responsible for 65.61 percent and 24.94 percent of costs, respectively. Median costs for patients submitted to surgical procedure until the fourth day of hospitalization were lower than median costs for patients submitted after the fourth day (R$ 2,136.45 and R$ 3,281.45, respectively, p<0.00001). A significant difference in average costs per type of surgical procedure was also observed. Cost associated to inpatient treatment of hip fractures in the elderly was higher in patients who performed surgery after the fourth day of hospitalization. Clinical hospitalization and surgical procedure were the main cost components observed.


Subject(s)
Humans , Male , Female , Aged , Antirheumatic Agents , Arthritis, Rheumatoid/economics , Arthritis, Rheumatoid/therapy , Cost-Effectiveness Analysis , Health Care Costs/ethics , Femoral Fractures/economics , Femoral Fractures/prevention & control , Practice Patterns, Physicians'/economics , Practice Patterns, Physicians'/ethics , Hospital Costs , Drug Costs/statistics & numerical data , Drug Costs/ethics , Fracture Fixation/economics , Fracture Fixation , Methotrexate/antagonists & inhibitors , Methotrexate/pharmacology , Methotrexate/therapeutic use , Surgical Procedures, Operative/economics , Sulfasalazine/economics , Sulfasalazine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...